Technical Data
AGR2 (Anterior Gradient Protein 2 Homolog, AG-2, hAG-2, HPC8, Secreted Cement Gland Protein XAG-2 homolog, AG2, UNQ515/PRO1030)
Agrin is an essential extracellular matrix component which promotes clustering of nicotinic acetylcholine receptors (nAChRs) and other proteins during development at the neuromuscular junction. Agrin, MuSK and Rapsyn are all essential components for AChR aggregation, through an unknown mechanism. The C-terminal region of agrin is released into the medium, interacts with receptors on the muscle surface and induces AChR aggregation. The central region contains two O-linked glycosylation sites and a domain homologous to domain III of laminin. The N-terminal region anchors agrin to the extracellular matrix via other basal membrane components. This region also contains a protease inhibitor domain and glycosaminoglycan attachment sites; increasing the predicted MW from 200kD to ~600kD.

Suitable for use in Western Blot, Immunoprecipitation and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:100
Immunohistochemistry: Frozen
Immunohistochemistry (formalin fixed paraffin embedded): 1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20CBlue IceHumanRabbit
Synthetic peptides corresponding to aa55-72 (TQTYEEALYKSKTSNKPL) of human AGR2; (Genbank accession no. NP_006399.1)
Purified by Protein G affinity Chromatography.
Supplied as a liquid in PBS, 0.05% BSA, 0.05% sodium azide.
Recognizes human AGR2 homolog. Species Crossreactivity: mouse. Species sequence homology: rat, chimpanzee, canine, bovine, xenopus, chicken, orangutan.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Fletcher GC et al.,Br J Cancer. 2003 Feb 24;88(4):579-85. 2. Petek E et al.,Cytogenet Cell Genet. 2000;89(3-4):141-2.